Loading
Companies get longer monopolies for rare and paediatric cancer drugs. That reward should come with a commitment to sell at cost in low-income countries.
Orphan, paediatric and data exclusivity extensions are valuable regulatory rewards granted without access conditions. The proposal is that regulators condition these extensions on a registered commitment: tiered pricing at or near cost in all low- and lower-middle-income countries, filing for registration in those countries within a year of first approval, and participation in pooled procurement. Non-compliance would shorten the exclusivity. Similar conditionality is used in some public research funding agreements and in the EU's 2023 pharmaceutical reform proposals linking exclusivity to launch in all member states.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value, Most of the world has almost no cancer care.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value, Most of the world has almost no cancer care.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.